Key Takeaways
- • Bill Ackman and his wife Neri Oxman are donating approximately $400 million in Pershing Square Inc. (NYSE:PS) stock to establish the Ackman Oxman Institute, a brain research facility in Manhattan focused on neuroscience and rehabilitation.
- • The 680,000-square-foot campus on Manhattan's West End Avenue will prioritize applied outcomes—cures, treatments, devices, rehabilitation, and exercise equipment—over academic publishing, positioning it as larger than Rockefeller University.
- • The initiative was catalyzed by Ackman's daughter Lucy's near-fatal brain hemorrhage in February 2026, which required emergency surgery; her ongoing recovery may involve brain-computer interface technology from companies including Neuralink, Precision Neuroscience, Science Corp, Synchron, and Nudge.
- • The institute's board includes inventor-engineer Dean Kamen and co-founder of Regeneron Pharmaceuticals, signaling deep scientific credibility and industry connectivity in the biotech and medical device sectors.
- • Ackman and Oxman had conceptualized a brain research institute five years prior following Oxman's mother's death from Alzheimer's, but the economics were not viable until Lucy's medical crisis provided both urgency and motivation for the $400 million commitment.
Summary
Billionaire hedge fund manager Bill Ackman and architect Neri Oxman announced a $400 million philanthropic commitment to establish the Ackman Oxman Institute, a dedicated brain research and rehabilitation center in Manhattan. The gift, structured as a donation of Pershing Square Inc. stock to a charitable foundation, represents one of the largest recent commitments to neuroscience infrastructure and research in the United States.
The institute's physical footprint will occupy approximately 680,000 square feet on Manhattan's West End Avenue—larger than the established Rockefeller University—and will adopt an applied research model prioritizing practical medical outcomes over academic publishing. According to Ackman, the facility will focus on "cures, treatments, devices, rehabilitation and exercise equipment," reflecting a direct translation of scientific discovery into patient-facing therapeutics and rehabilitation technologies.
The impetus for the accelerated timeline stems from a personal health crisis. In February 2026, Ackman's 26-year-old daughter Lucy was discovered unconscious in her Brooklyn apartment after suffering a massive brain hemorrhage. Emergency surgery relieved intracranial pressure and saved her life. Ackman has publicly noted that Lucy's months-long recovery has yielded significant cognitive restoration and early progress in mobility with assistance, though she remains blind. He emphasized that "now is the best time in history" for such a devastating injury to occur, given advances in neurotechnology and rehabilitation science.
Lucy's rehabilitation pathway is expected to incorporate emerging brain-computer interface (BCI) technologies from Neuralink (founded by Elon Musk), as well as competitors including Precision Neuroscience, Science Corp, Synchron, and Nudge. This constellation of partners positions the institute at the intersection of neural engineering and clinical application—a strategic alignment that may accelerate the translation of BCI research into therapeutic use cases.
The genesis of the institute predates Lucy's hemorrhage by five years. Ackman and Oxman had previously explored launching a brain research institute, motivated by the death of Oxman's mother from Alzheimer's disease, but deemed the economics unfeasible at that time. The personal health event provided both emotional urgency and financial catalyst to advance the project. The institute's board includes Dean Kamen, the inventor-engineer and founder of FIRST robotics, and co-founder of Regeneron Pharmaceuticals, lending significant scientific and commercial credibility to the enterprise.
The institute's physical footprint will occupy approximately 680,000 square feet on Manhattan's West End Avenue—larger than the established Rockefeller University—and will adopt an applied research model prioritizing practical medical outcomes over academic publishing. According to Ackman, the facility will focus on "cures, treatments, devices, rehabilitation and exercise equipment," reflecting a direct translation of scientific discovery into patient-facing therapeutics and rehabilitation technologies.
The impetus for the accelerated timeline stems from a personal health crisis. In February 2026, Ackman's 26-year-old daughter Lucy was discovered unconscious in her Brooklyn apartment after suffering a massive brain hemorrhage. Emergency surgery relieved intracranial pressure and saved her life. Ackman has publicly noted that Lucy's months-long recovery has yielded significant cognitive restoration and early progress in mobility with assistance, though she remains blind. He emphasized that "now is the best time in history" for such a devastating injury to occur, given advances in neurotechnology and rehabilitation science.
Lucy's rehabilitation pathway is expected to incorporate emerging brain-computer interface (BCI) technologies from Neuralink (founded by Elon Musk), as well as competitors including Precision Neuroscience, Science Corp, Synchron, and Nudge. This constellation of partners positions the institute at the intersection of neural engineering and clinical application—a strategic alignment that may accelerate the translation of BCI research into therapeutic use cases.
The genesis of the institute predates Lucy's hemorrhage by five years. Ackman and Oxman had previously explored launching a brain research institute, motivated by the death of Oxman's mother from Alzheimer's disease, but deemed the economics unfeasible at that time. The personal health event provided both emotional urgency and financial catalyst to advance the project. The institute's board includes Dean Kamen, the inventor-engineer and founder of FIRST robotics, and co-founder of Regeneron Pharmaceuticals, lending significant scientific and commercial credibility to the enterprise.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.